tbuckley/cabot-search huggingface dataset:
SAT0495 Up-Regulated Soluble BCL-2: A Unique Profile of Patients with Juvenile Dermatomyositis (JDM): Table 1.
Authors: B.L. Liphaus, M.H.B. Kiss, A.E. Sallum, N.E. Aikawa, S. Carrasco, P. Palmeira, L. Lima, C.A. Silva, C. Goldenstein-Schainberg, M. Carneiro-Sampaio
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> JDM has distinct clinical, immunologic and pathological features compared with patients of adult onset. Studies have evidenced Fas, Fas ligand (FasL), TNF related apoptosis inducing ligand (TRAIL) and Bcl-2 altered expressions in both muscle fibers and inflammatory cells in biopsies from adult and juvenile dermatomyositis.<sup>1-5</sup> The role of soluble apoptosis molecules in JDM is not yet defined. <h3>Objectives</h3> This study assessed soluble Fas, FasL, TRAIL and Bcl-2 in JDM patients and evaluated the relation with disease activity markers. <h3>Methods</h3> sFas, sFasL, sTRAIL and sBcl-2 levels were measured in sera from 34 JDM patients (22 girls, mean age 10.8 yrs, Bohan and Peter criteria), 40 gender and age matched healthy individuals (26 girls, mean age 10.7 yrs), 33 JIA patients (20 girls, mean age 11.9 yrs) and 41 JSLE patients (20 girls, mean age 12.2 yrs) as disease controls. Soluble apoptosis molecules were quantified by commercial ELISA Kits following manufacturer9s instructions. Disease activity markers included ERS (Westergreen), CRP (nephelometry), CMAS and MMT. Statistical analysis used nonparametric Kruskal-Wallis test and Spearman9s rank. P-values&lt;0.05 were considered significant. <h3>Results</h3> JDM patients presented significant increased sBcl-2 levels compared with healthy controls which negatively correlated with CRP (r=0.55; p=0.01). sFas and sTRAIL were similar to controls and sFasL was detected in only one patient (0.32 ng/ml). JIA patients had sFas, sFasL, sTRAIL and sBcl-2 similar to healthy controls. In contrast, JSLE patients had increased sFas and sTRAIL, decreased sFasL and similar sBcl-2 levels compared with controls (Table). <h3>Conclusions</h3> JDM patients presented a unique profile of soluble apoptosis molecules characterized by increased sBcl-2 levels, contrasting with the results of adult patients that had increased sFas, and similar sFasL levels.<sup>6,7</sup> This particular profile may contribute to disease pathogenesis and is distinct from those presented by JIA and JSLE patients. <h3>References</h3> Zhao Y, et al. Clin Immunol. 2007;125:165-72. De Bleecker JL, et al. Acta Neuropathol. 2001;101:572-78. Sugira T, et al. Arthritis Rheum. 1999;42:291-8. Behrens L, et al. Brain 1997;120:929-38. Falcini F, et al. Clin Exp Rheumatol. 2000;18:643-6. Nozawa H, et al. Arthritis Rheum. 1997;40:1126-9. Sahin M, et al. Clin Bioch 2007;40:6-10. <h3>Acknowledgements</h3> We thank FAPESP (grants 2012/22997-4 and 2008/58238-4) for supporting this study. <h3>Disclosure of Interest</h3> None declared
Handbook of Assessment and Treatment of Eating Disordersedited by B. Timothy Walsh, M.D., Evelyn Attia, M.D., Deborah R. Glasofer, Ph.D., and Robyn Sysko, Ph.D. Washington, D.C., American Psychiatric Association Publishing, 2016, 358 pp., $59.00 (paperback).
Authors: Patricia Westmoreland, Philip S. Mehler
Journal: American Journal of Psychiatry (2016)
Physician spending and risk of malpractice claims: defensive medicine may not be as common as we think
Authors: Daniel A Waxman, Hemal K Kanzaria
Journal: BMJ (2015)

Jena and colleagues start with the premise that defensive medicine is common.1 It is clear, however, that the physician surveys they cite cannot be taken at face value.2 3 Defensive practice may be just one reason that physicians practice “resource intensive medicine.” …
Transitional Cell Carcinoma of the Renal Pelvis and Its Expression of p53 Protein, c-erbB-2 Protein, Neuron-Specific Enolase, Phe 5, Chromogranin, Laminin and Collagen Type IV
Authors: Bodil Bjerkehagen, Sophie Dorothea Fosså, Nils Raabe, Ruth Holm, Jahn M. Nesland
Journal: European Urology (1994)
Beryllium disease and sarcoidosis: still besties after all these years?
Authors: Daniel A. Culver
Journal: European Respiratory Journal (2016)

Toxic pulmonary disease from beryllium exposure first came to light in the 1930s, soon after the emergence of industrial uses of beryllium alloys. An early manufacturing application for beryllium compounds, as phosphors in fluorescent tubes, was the cause of some of the first known cases of chronic beryllium disease (CBD) (first termed "pulmonary granulomatosis of beryllium workers"). However, the association between beryllium and granulomatous inflammation was controversial at the outset, leading to the moniker "Salem sarcoid" to describe the outbreak of "sarcoidosis" among fluorescent bulb workers at a manufacturing plant in Salem, MA, USA [1]. Despite opposition from the manufacturer and its allies in the state government, H. Hardy convincingly established the relationship between beryllium exposure and granulomatous disease with her landmark analysis of 17 workers from the Salem light bulb factory [2]. Her key insight was to identify the high frequency of latency of disease onset and progression after cessation of exposure. Nearly a century later, despite subtle clinical and radiological differences, the salient features of pulmonary sarcoidosis and CBD continue to be nearly indistinguishable, leading to occasional suggestions that CBD may be simply "sarcoidosis of known cause" [3]. Despite advances, the pathobiology of chronic beryllium disease and sarcoidosis continue to overlap more than differ <http://ow.ly/4n6FcL>
Tell It Like It Is
Authors: Thomas J. Smith
Journal: Journal of Clinical Oncology (2000)

Article Tools ART OF ONCOLOGY: WHEN THE TUMOR IS NOT THE TARGET Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.19.3441 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 11013287 Tell It Like It Is Thomas J. SmithxThomas J. SmithSearch for articles by this author Show More From the Division of Hematology/Oncology, Department of Internal Medicine, Medical College of Virginia/Virginia Commonwealth University, Richmond, VA. https://doi.org/10.1200/JCO.2000.18.19.3441 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical Oncology
IL-17A enhances IL-13 activity by enhancing IL-13–induced signal transducer and activator of transcription 6 activation
Authors: Sara L. Hall, Theresa Baker, Stephane Lajoie, Phoebe K. Richgels, Yanfen Yang, Jaclyn W. McAlees, Adelaide van Lier, Marsha Wills-Karp, Umasundari Sivaprasad, Thomas H. Acciani, Timothy D. LeCras, Jocelyn Biagini Myers, Melinda Butsch Kovacic, Ian P. Lewkowich
Journal: Journal of Allergy and Clinical Immunology (2016)
Method of Biological Assay of Compounds Effective in the Treatment of IRC 741 Leukemia in Fischer Rats&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Veronica Armaghan
Journal: JNCI Journal of the National Cancer Institute (1960)

An assay system with a wide range for testing carcinolytic compounds in the development of the transplantable acute leukemia IRC 741 in Fischer rats is described. By initiating treatment at intervals of 1, 2, 4, 6, 8, and 10 days after transplantation, it is possible to show differences in response to compounds which are not discernible when testing is limited only to early and established tumors. The method is presented as a biological tool for demonstrating differences in response that may result from modifications of active antileukemic compounds. The common denominator for comparison may be dosage and/or treatment schedule, percent cures on day 1, or 2, vehicle, or route of administration of the compound. The method may also be used in selecting an optimum regimen of treatment for a compound. The application of this procedure to other tumor systems has been suggested.
Experiment versus Authority
Authors: Duncan P. Thomas
Journal: New England Journal of Medicine (1969)

IT is generally agreed today that the advent of the controlled clinical trial has been one of the most notable advances in modern medical practice. The type of trial that has evolved over the past 25 years is recognized as an essential part of the clinical evaluation of remedies.1 There is increasing interest in evaluating the effects of surgical operations, as well as drugs, by the method of a controlled trial. It has become apparent that the only way to separate the effects of most types of therapy from those of patient selection is by a study in which patients . . .
AB0710 Causes and Risk Factors for Death in Systemic Sclerosis – Experience of a Eustar Center
Authors: L. Groseanu, T. Gudu, D. Predeteanu, A. Balanescu, V. Bojinca, I. Saulescu, D. Opris, A. Borangiu, C. Constantinescu, M.-M. Negru, F. Berghea, M. Abobului, R. Ionescu
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic sclerosis (SSc) has a case-based mortality that is one of the highest among the rheumatic diseases. <h3>Objectives</h3> To identity predictors of mortality in patients with systemic sclerosis from their first evaluation in a reference center <h3>Methods</h3> 90 SSc patients were followed between JAN 2010 – JAN 2015. A complete baseline evaluation of all patients was done according to MEDS evaluation sheets (demographics, disease history, main organ involvement). A complete follow-up was done every year. Univariate and multivariate predictors of survival were assessed using proportional hazards regression modelling <h3>Results</h3> Amongst the cohort of 90 patients the mean age at diagnosis was 55,65 (SD 12,45) years, medium disease duration was 11,7 (SD 6,9) years. Medium disease activity score was 3,43 (SD 2,14) years. In the deceased group (10 patients), the mean age of death was 43,7 years (SD 8,9 years). The 5- year survival rate at was 88,88%. The most common cause of SSc-related mortality was pulmonary complications (60%). 70% of deaths were attributed directly to SSc. Of the SSc-related deaths, 28,57% were attributed to pulmonary fibrosis, 57,14% to pulmonary arterial hypertension (PAH) and 14,28% to cardiac causes (arrhythmias). Among the non-SSc-related causes, infections (33%) and malignancies (33%) were followed by indidental causes (33%). Sex- and age-adjusted univariate analysis identified the diffuse subset, a modified Rodnan score (mRSS)&gt;14, pulmonary fibrosis, pulmonary hypertension, scleroderma renal crisis and a Medsger score&gt;10 to be associated with increased mortality in all patients. Sex- and age-adjusted multivariate model identified a mRSS &gt;14 OR 1,562 [1.00; 2.42] and pulmonary hypertension OR 1.336 [1.03; 1.73] as predictors of death. <h3>Conclusions</h3> Disease-related causes, in particular pulmonary hypertension and pulmonary fibrosis accounted for the majority of deaths in SSc. Mortality rate in the center seems to be a little bit higher than the EUSTAR cohort, especially in patients with pulmonary hypertension possibly related to difficult acces to specific vasodilator treatment. Higher Rodnan skin scores at baseline evaluation still remains an important mortality predictor. <h3>References</h3> Nikpour M, Baron M. Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies. Curr Opin Rheumatol. 2014;26(2):131-7 Tyndall AJ, Bannert B, Vonk M, Airò P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database.Ann Rheum Dis. 2010 Oct;69(10):1809-1 <h3>Disclosure of Interest</h3> None declared
Vitamin A and Cancer Prevention Conference—An Introduction&lt;xref ref-type="fn" rid="FN1"&gt;1&lt;/xref&gt;
Authors: B A Underwood
Journal: JNCI Journal of the National Cancer Institute (1984)

Journal Article Vitamin A and Cancer Prevention Conference—An Introduction Get access Barbara A. Underwood Barbara A. Underwood 3 3Address reprint requests to Dr. Underwood, Building 31, Room 6A08, National Institutes of Health, Bethesda, Md. 20205. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 73, Issue 6, December 1984, Pages 1371–1372, https://doi.org/10.1093/jnci/73.6.1371 Published: 01 December 1984
Detection of a Single Base Mutation in the Human Dihydrofolate Reductase Gene from a Methotrexate-Resistant Cell Line Using the Polymerase Chain Reaction
Authors: A P Dicker, M Volkenandt, J R Bertino
Journal: Cancer Communications (1989)

To test the utility of the polymerase chain reaction in identifying single base mutations in a gene known to give rise to an altered enzyme and drug resistance phenotype, a human colon adenocarcinoma cell line resistant to methotrexate, with a known single base mutation (Srimatkandada et al., J. Biol. Chem. 264:3524, 1989) was examined. Poly A+ RNA was used for cDNA synthesis with reverse transcriptase, deoxynucleoside triphosphates, and 5 microM 3' primer that anneals outside the coding region of the human dihydrofolate reductase. The RNA:DNA hybrid was used as a template for the polymerase chain reaction with the addition of a 5' primer and Thermus aquaticus (Taq)I DNA polymerase. These primers flank the coding region of the human dihydrofolate reductase and define a region of 650 bases. The polymerase chain reaction was carried out for 40 cycles resulting in full length transcripts in microgram amounts clearly visible by ethidium bromide staining on agarose gels. DNA was isolated by standard methods, and double-stranded DNA was sequenced by the chain-termination method using TaqI DNA polymerase. A single point mutation was discovered at position 91 (T----C) resulting in a substitution of serine for phenylalanine at codon 31, as determined previously by classical cDNA cloning and sequencing. Sequence analysis indicated that this base transition resulted in the loss of Eco RI and Xmn I sites and the gain of a HinfI site in the cDNA, which were confirmed by restriction digests.(ABSTRACT TRUNCATED AT 250 WORDS)
Primer on the Rheumatic Diseases
Authors: J C MCDONALD, F MILGROM, E WITEBSKY
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
PTH-252 Investigation of iron deficiency anaemia. duodenal biopsies – are they worth it?
Authors: S Paremal, S Nair, A Boyd, J Robertson, M Gunn, C Mountford
Journal: Gut (2015)

<h3>Introduction</h3> The prevalence of iron deficiency anaemia (IDA) in adult men and postmenopausal women in the developed world is 2–5%.<sup>1</sup>British Society of Gastroenterology (BSG) IDA Guidelines recommend tissue transglutaminase (tTG) antibody as a screening test for coeliac disease. Indications for duodenal biopsies include patients with diarrhoea, weight loss and positive tTG serology. Where coeliac serology is positive, duodenal bulb and D2 biopsies should be taken.<sup>2 </sup>BSG IDA Guidelines do not recommend duodenal biopsy for tTG negative, asymptomatic patients.<sup>3</sup>However a separate BSG guideline for diagnosis of coeliac disease recommends duodenal biopsies in IDA patients irrespective of Coeliac serology due to the finding of seronegative coeliac disease.<sup>2</sup> <h3>Method</h3> This audit was carried out to assess adherence to BSG IDA Guidelines for duodenal biopsies in patients referred for IDA investigation with negative tTG antibodies. The study also set out to establish the positive diagnostic yield where biopsies were taken in the same cohort. Patients referred to Newcastle upon Tyne NHSFT adult IDA service between 2011 and 2014 identified as ttG negative and who underwent endoscopy were included. <h3>Results</h3> Two hundred patients were identified, median age 66 (range 19–91); 126 (63%) female and 74 (37%) Male. 114 (57%) patients had duodenal biopsies taken despite tTG being negative and asymptomatic. 28 (19.7%) patients were symptomatic and duodenal biopsies taken, though only 8 (28%) of these patients had 4 biopsy samples and none were from duodenal bulb. Where biopsies were taken, none confirmed coeliac disease. 5/142 (3.5%) patients biopsied had lymphocytic duodenitis but none of them were subsequently diagnosed or treated as coeliac disease. <h3>Conclusion</h3> Duodenal sampling in tTG negative patients did not yield any additional positive diagnosis of coeliac disease. This confirms the recommendations of BSG IDA guidelines. The results of this audit do not appear to support the recommendations made within the BSG coeliac disease guideline for duodenal biopsy being performed regardless of coeliac serology. However, the fact that only 4.9% of patients who had duodenal biopsies taken had duodenal bulb sampled, may limit this conclusion. More efficient use of local endsoscopy and pathology resources can occur by appropriate selection of patients on whom to perform duodenal biopsies. <h3>Disclosure of interest</h3> None Declared. <h3>References</h3> Guralnik JM, Eisenstaedt RS, Ferrucci L, <i>et al</i>. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anaemia. Blood 2004;<b>104</b>:2263e8 Diagnosis and management of adult coeliac disease: Guidelines from British Society of Gastroenterology June10, 2014(10.1136/gutjnl-2013-306578) BSG Guidelines for the management of Iron deficiency anaemia May 2011
MOPP after two decades.
Authors: D L Longo, R C Young, P L Duffey, S M Hubbard, V T DeVita
Journal: Journal of Clinical Oncology (1987)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1987.5.2.320 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3806177 MOPP after two decades. D L LongoxD L LongoSearch for articles by this author , R C YoungxR C YoungSearch for articles by this author , P L DuffeyxP L DuffeySearch for articles by this author , S M HubbardxS M HubbardSearch for articles by this author , V T DeVita JrxV T DeVita JrSearch for articles by this author https://doi.org/10.1200/JCO.1987.5.2.320 PDF "MOPP after two decades.." Journal of Clinical Oncology, 5(2), pp. 320–321© 1987 by American Society of Clinical Oncology
SP0185 Intensity Levels of Exercise and Physical Activity in Rheumatic Diseases, and How to Measure them
Authors: H. Dagfinrud
Journal: Annals of the Rheumatic Diseases (2015)

Exercises have traditionally been recommended as part of the management program for patients with rheumatic diseases, and the main aim has been on flexibility exercises for improved or maintained joint mobility. However, the last decade has brought new insight into the increased risk of cardiovascular disease following inflammatory diseases. To meet this challenge, the focus for exercise programs should be broadened to target also cardiorespiratory fitness (CRF) and muscle strength. Effects of CRF and strength training are dependent on the intensity, duration and frequency of exercises and evidence-based recommendations for quantity and quality of exercise for developing and maintaining CRF and muscle strength are published (Garber et al 2011). These recommendations may apply also for most people with rheumatic diseases, but individual adjustments may be needed, taking disease activity and severity into account. As defined levels of intensity are needed to obtain specific physiological responses of exercises, testing and monitoring patients are required. Maximal oxygen uptake (VO<sub>2max</sub>) can be measured by direct and indirect methods. Direct tests (measuring gas exchange during maximal work) are regarded as the gold standard, but are not feasible for use in clinical practice, as advanced laboratory device is required. Several indirect tests are available for prediction of VO<sub>2max</sub> from different mathematical equations. The estimation is based on the heart rate response to submaximal work on a treadmill or a bicycle ergometer. A heart rate monitor and/or a scale for personal rating of exertion (i.e Borg Scale) may be used to control the intensity level. For research purpose, muscle strength can be measured by isokinetic tests with advanced equipment. In clinical practice, the 1 repetition maximum method (1RM) method can be used for measuring dynamic body-strength, and grip strength can easily be measured with a dynamometer. Further, a wide range of functional tests are available, often useful in rehabilitation, as they capture a combination of muscular strength, CRF, functional capacity and balance. <h3>Disclosure of Interest</h3> None declared
Research training in psychiatry: a survey of current practices
Authors: G D Strauss, J Yager, D Offer
Journal: American Journal of Psychiatry (1980)

The authors surveyed current opportunities and research training practices in psychiatric residency programs. Although most programs offer at least a journal club and manb state that research experiences are available, very limited research resources are available to residents in many programs. The availability of research teaching is quite variable, and few programs budget or spend money for resident research. Further, very few programs require any direct reesarch experience. These findings offer a partial explanation for the shortage of research psychiatrists.
The role of the activation of mTOR pathway in patients with advanced neuroendocrine tumors treated with everolimus
Authors: F. Gelsomino, G. Rossi, A. Spallanzani, F. Bertolini, A. Fontana, V.A. Tamma, S. Zironi, R. Depenni, K. Di Emidio, G. Luppi
Journal: Annals of Oncology (2015)
Immunosuppression and Experimental Lymphoma
Authors: Gerhard R. F. Krueger
Journal: JNCI Journal of the National Cancer Institute (1973)

Journal Article Immunosuppression and Experimental Lymphoma Get access Gerhard R. F. Krueger, M.D. Gerhard R. F. Krueger, M.D. Pathology Institute University of Cologne, Cologne 41, Germany Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 50, Issue 5, May 1973, Page 1412, https://doi.org/10.1093/jnci/50.5.1412-a Published: 01 May 1973